Agilent Technologies, Inc. has signed a definitive agreement to acquire Seahorse Bioscience, a provider of instruments and assay kits for measuring cell metabolism and bioenergetics, for $235 million in cash.   Seahorse’s technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted by the introduction of a specific drug, by providing real-time kinetics to unlock essential cellular bioenergetics data.   Scientists use Seahorse...